| Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer SA Tomlins, DR Rhodes, S Perner, SM Dhanasekaran, R Mehra, XW Sun, ... science 310 (5748), 644-648, 2005 | 4072 | 2005 |
| The polycomb group protein EZH2 is involved in progression of prostate cancer S Varambally, SM Dhanasekaran, M Zhou, TR Barrette, C Kumar-Sinha, ... Nature 419 (6907), 624-629, 2002 | 2707 | 2002 |
| Integrative clinical genomics of advanced prostate cancer D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ... Cell 161 (5), 1215-1228, 2015 | 2080 | 2015 |
| Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer JS De Bono, HI Scher, RB Montgomery, C Parker, MC Miller, H Tissing, ... Clinical cancer research 14 (19), 6302-6309, 2008 | 2021 | 2008 |
| Delineation of prognostic biomarkers in prostate cancer SM Dhanasekaran, TR Barrette, D Ghosh, R Shah, S Varambally, ... Nature 412 (6849), 822-826, 2001 | 1955 | 2001 |
| The mutational landscape of lethal castration-resistant prostate cancer CS Grasso, YM Wu, DR Robinson, X Cao, SM Dhanasekaran, AP Khan, ... Nature 487 (7406), 239-243, 2012 | 1900 | 2012 |
| Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone RS Taichman, C Cooper, ET Keller, KJ Pienta, NS Taichman, ... Cancer research 62 (6), 1832-1837, 2002 | 1172 | 2002 |
| Integrative molecular concept modeling of prostate cancer progression SA Tomlins, R Mehra, DR Rhodes, X Cao, L Wang, SM Dhanasekaran, ... Nature genetics 39 (1), 41-51, 2007 | 946 | 2007 |
| Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer SA Tomlins, B Laxman, SM Dhanasekaran, BE Helgeson, X Cao, ... Nature 448 (7153), 595-599, 2007 | 877 | 2007 |
| Activating ESR1 mutations in hormone-resistant metastatic breast cancer DR Robinson, YM Wu, P Vats, F Su, RJ Lonigro, X Cao, ... Nature genetics 45 (12), 1446, 2013 | 842 | 2013 |
| α-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer MA Rubin, M Zhou, SM Dhanasekaran, S Varambally, TR Barrette, ... Jama 287 (13), 1662-1670, 2002 | 806 | 2002 |
| Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression S Varambally, J Yu, B Laxman, DR Rhodes, R Mehra, SA Tomlins, ... Cancer cell 8 (5), 393-406, 2005 | 770 | 2005 |
| Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition S Shangary, D Qin, D McEachern, M Liu, RS Miller, S Qiu, ... Proceedings of the National Academy of Sciences 105 (10), 3933-3938, 2008 | 703 | 2008 |
| Autoantibody signatures in prostate cancer X Wang, J Yu, A Sreekumar, S Varambally, R Shen, D Giacherio, R Mehra, ... New England Journal of Medicine 353 (12), 1224-1235, 2005 | 703 | 2005 |
| CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression X Sun, G Cheng, M Hao, J Zheng, X Zhou, J Zhang, RS Taichman, ... Cancer and Metastasis Reviews 29 (4), 709-722, 2010 | 701 | 2010 |
| Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program RB Shah, R Mehra, AM Chinnaiyan, R Shen, D Ghosh, M Zhou, ... Cancer research 64 (24), 9209-9216, 2004 | 650 | 2004 |
| A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth Q Wang, W Li, XS Liu, JS Carroll, OA Jänne, EK Keeton, AM Chinnaiyan, ... Molecular cell 27 (3), 380-392, 2007 | 638 | 2007 |
| Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument P Esper, FEI Mo, G Chodak, M Sinner, D Cella, KJ Pienta Urology 50 (6), 920-928, 1997 | 604 | 1997 |
| Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow Y Shiozawa, EA Pedersen, AM Havens, Y Jung, A Mishra, J Joseph, ... The Journal of clinical investigation 121 (4), 1298-1312, 2011 | 599 | 2011 |
| Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data HI Scher, X Jia, JS de Bono, M Fleisher, KJ Pienta, D Raghavan, G Heller The lancet oncology 10 (3), 233-239, 2009 | 597 | 2009 |
Mark A RubinProfessor & Director Department for BioMedical Research, University of BernVerified email at dbmr.unibe.ch
